ABIOMED, Inc. (ABMD) Shares Bought by Country Trust Bank

Country Trust Bank grew its holdings in ABIOMED, Inc. (NASDAQ:ABMD) by 11.1% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 106,931 shares of the medical equipment provider’s stock after buying an additional 10,667 shares during the quarter. ABIOMED makes up 1.4% of Country Trust Bank’s portfolio, making the stock its 25th largest position. Country Trust Bank owned 0.24% of ABIOMED worth $30,538,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in ABMD. Sontag Advisory LLC acquired a new stake in ABIOMED in the 4th quarter valued at approximately $25,000. We Are One Seven LLC acquired a new position in shares of ABIOMED during the 4th quarter worth approximately $26,000. Cornerstone Advisors Inc. increased its position in shares of ABIOMED by 304.8% during the 4th quarter. Cornerstone Advisors Inc. now owns 85 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 64 shares during the last quarter. Shine Investment Advisory Services Inc. increased its position in shares of ABIOMED by 319.0% during the 4th quarter. Shine Investment Advisory Services Inc. now owns 88 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 67 shares during the last quarter. Finally, Captrust Financial Advisors increased its position in shares of ABIOMED by 1,187.5% during the 4th quarter. Captrust Financial Advisors now owns 103 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 95 shares during the last quarter. Institutional investors own 87.99% of the company’s stock.

Several research analysts have weighed in on ABMD shares. BidaskClub lowered ABIOMED from a “hold” rating to a “sell” rating in a research report on Thursday, March 7th. ValuEngine lowered ABIOMED from a “buy” rating to a “hold” rating in a report on Wednesday, February 27th. Zacks Investment Research lowered ABIOMED from a “buy” rating to a “hold” rating in a report on Tuesday, January 29th. Finally, BTIG Research reissued a “buy” rating and set a $400.00 target price on shares of ABIOMED in a report on Tuesday, January 22nd. They noted that the move was a valuation call. Three research analysts have rated the stock with a sell rating and five have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $408.67.

Shares of NASDAQ:ABMD traded up $1.67 during trading on Thursday, reaching $261.94. 712,900 shares of the company traded hands, compared to its average volume of 665,254. The company has a market cap of $11.73 billion, a price-to-earnings ratio of 72.76, a PEG ratio of 2.04 and a beta of 0.29. ABIOMED, Inc. has a 52 week low of $228.00 and a 52 week high of $459.75.

ABIOMED (NASDAQ:ABMD) last released its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.07 by $0.53. ABIOMED had a return on equity of 20.32% and a net margin of 33.66%. The firm had revenue of $207.08 million during the quarter, compared to the consensus estimate of $218.88 million. During the same period in the prior year, the company posted $0.80 EPS. The company’s revenue was up 18.7% compared to the same quarter last year. On average, analysts expect that ABIOMED, Inc. will post 4.78 EPS for the current fiscal year.

In other ABIOMED news, Director Martin P. Sutter sold 5,000 shares of the company’s stock in a transaction dated Wednesday, February 13th. The stock was sold at an average price of $360.00, for a total value of $1,800,000.00. Following the completion of the transaction, the director now owns 195,491 shares of the company’s stock, valued at approximately $70,376,760. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Martin P. Sutter sold 20,000 shares of the company’s stock in a transaction dated Friday, February 15th. The stock was sold at an average price of $360.16, for a total value of $7,203,200.00. Following the completion of the transaction, the director now directly owns 195,491 shares of the company’s stock, valued at approximately $70,408,038.56. The disclosure for this sale can be found here. 3.50% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This report was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/05/10/country-trust-bank-has-30-54-million-stake-in-abiomed-inc-abmd.html.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Featured Story: Calculate Your Return on Investment (ROI)

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.